Ning Jia

Ning Jia

Auto-generated profile, based on publicly available information

Ning Jia

Department of Biochemistry, SUSTech Homeostatic Medicine Institute, School of Medicine, Southern University of Science and Technology, Shenzhen, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2021 in Nature Reviews Molecular Cell Biology
Verified
Journal Article
Closed access
PDF file
NJNing Jia
Ning Jia
DPDinshaw J. Patel
Dinshaw J. Patel

3 July 2020 in Science
Verified
Journal Article
Closed access
PDF file
AMAlexander J. Meeske
Alexander J. Meeske
NJNing Jia
Ning Jia
ACAlice K. Cassel
Alice K. Cassel
AKAlbina Kozlova
Albina Kozlova
JLJingqiu Liao
Jingqiu Liao
LMLuciano A. Marraffini
Luciano A. Marraffini
An infallible inhibitor of Cas13: CRISPR-Cas13 protects bacterial populations from viral infections by indiscriminately destroying the RNA of the cell and its invader, simultaneously arresting the growth of infected hosts and the spread of the virus. This response is mediated by the Cas13 nuclease, which unleashes massive RNA degradation after recognition of viral transcripts that are complementary to its guide RNA. Meeske et al. discovered AcrVIA1, a viral-encoded inhibitor that binds to Cas13 to occlude the RNA guide and prevent the activation of the nuclease (see the Perspective by Barrangou and Sontheimer). As opposed to inhibitors of DNA-cleaving CRISPR-Cas systems, which require multiple infections to neutralize all Cas nucleases of the host, production of AcrVIA1 by a single virus is sufficient to overcome the CRISPR-Cas13 response. Science , this issue p. 54 ; see also p. 31

19 June 2025 in Science
Verified
Journal Article
Closed access
XSXin-Yi Song
Xin-Yi Song
YXYushan Xia
Yushan Xia
JZJun-Tao Zhang
Jun-Tao Zhang
YLYu-Jun Liu
Yu-Jun Liu
HQHua Qi
Hua Qi
NJNing Jia
Ning Jia
Prokaryotic defense-associated reverse transcriptases (DRTs) were recently identified with antiviral functions; however, their functional mechanisms remain largely unexplored. Here we show that DRT9 forms a hexameric complex with its upstream noncoding RNA (ncRNA) to mediate antiphage defense by inducing cell growth arrest through abortive infection. Upon phage infection, the phage-encoded ribonucleotide reductase NrdAB complex increases intracellular deoxyadenosine triphosphate levels, activating DRT9 to synthesize long, polyadenylate [poly(A)]–rich single-stranded complementary DNA (cDNA), which likely sequesters the essential phage single-stranded DNA binding (SSB) protein and disrupts phage propagation. We further determined the cryo–electron microscopy structure of the DRT9-ncRNA hexamer complex, providing mechanistic insights into its cDNA synthesis. These findings highlight the diversity of RT-based antiviral defense mechanisms, expand our understanding of RT biological functions, and provide a structural basis for developing DRT9-based biotechnological tools.

20 June 2023 in Molecular Cell
Verified
Journal Article
Closed access
NCNing Cui
Ning Cui
JZJun-Tao Zhang
Jun-Tao Zhang
YLYongrui Liu
Yongrui Liu
YLYanhong Liu
Yanhong Liu
XLXiao-Yu Liu
Xiao-Yu Liu
NJNing Jia
Ning Jia

6 November 2023 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
JZJun-Tao Zhang
Jun-Tao Zhang
XWXin-Yang Wei
Xin-Yang Wei
NCNing Cui
Ning Cui
RTRuilin Tian
Ruilin Tian
NJNing Jia
Ning Jia

1 July 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
YZYu Zhang
Yu Zhang
TZTingting Zhang
Tingting Zhang
XXXue Xiao
Xue Xiao
YWYejun Wang
Yejun Wang
AKAdam Kawalek
Adam Kawalek
XLXue Liu
Xue Liu
With the rise of antibiotic-resistant bacteria, non-antibiotic therapies like gallium gain increasing attention. Intravenous gallium nitrate is under Phase II clinical trials to treat chronic Pseudomonas aeruginosa infections in cystic fibrosis patients. However, its clinical efficacy is constrained by the achievable peak concentration in human tissue. To address this limitation, we apply a genome-wide CRISPR interference approach (CRISPRi-seq) to identify potential synergistic targets with gallium. We classify the essential genes by response time and growth reduction, pinpointing the most vulnerable therapeutic targets in this species. In addition, we identify a highly conserved gene, fprB, encoding a ferredoxin-NADP⁺ reductase, whose deletion sensitizes P. aeruginosa to gallium, lowering its MIC by 32-fold and shifting mode of action from bacteriostatic to bactericidal. Further investigation reveals that FprB plays a critical role in modulating oxidative stress induced by gallium, via control of iron homeostasis and reactive oxygen species accumulation. Deleting fprB enhances gallium’s efficacy against biofilm formation and improves outcomes in a murine lung infection model of P. aeruginosa, suggesting FprB is a promising drug target in combination with gallium. Overall, our data show CRISPRi-seq as a powerful tool for systematic genetic analysis of P. aeruginosa, advancing the identification of novel therapeutic targets.